Vol.4, No.1 (2011), 91-102 AZ8.
C H CO6
5
4N(CH )
C H NO 37
32
4
4
596.6
215
CHCl
3
6.29
167.1 3
C, 74.48; H, 5.43; N, 9.37; O, 10.72
5.34
164.3 4 169.7 7 177.7
C, 73.88; H,4.73; N, 7.37; O, 14.02 C, 77.88; H, 5.43; N, 7.77; O, 8.92 C, 76.28; H, 5.83; N, 9.67; O, 8.22
164.3 4
C,75.68; H, 5.23; N, 7.57; O, 11.52
3 2
AZ9.
C H CO-
2-OH
C3 H N O
569.6
175
CHCl /CCl
AZ10.
C H CH -
H
C H NO
539.6
151
CHCl
AZ11.
C H CH -
4N(CH )
C H NO
582.6
182
CHCl
AZ12.
C H CH -
2-OH
C H NO
555.6
149
CHCl /CCl
6
5
6 5
2
6 5
2
5
35
37
27
29
34
3
3
4
5
3
3
3
4
5.6
3
6.01
3
3 2
6 5
2
% Inhibition = (1- Vt / Vc) x 100,
35
29
3
4
3
4
5.34
Vt = Mean volume of the test drug Vc = Mean volume of the control
Table-2: Anti-inflammatory in vitro activity of compounds AZ1-AZ12 % Protection Compound 30 min 1h 2h AZ1 35±1.793 47±1.444 49± 1.876 AZ2 39±1.881 49± 1.643 53± 1.372 AZ3 44±1.079 47± 1.377 52±2.46 AZ4 39±2.198 49± 1.404 57± 1.729 AZ5 35±1.472 47± 2.174 49±1.752 AZ6 39±2.66 48±1.872 54±1.4111 AZ7 39±1.831 42± 1.472 49± 1.876 AZ8 35±1.333 39±2.357 47±1.875 AZ9 36±1.831 39± 2.412 43± 1.163 AZ10 27± 1.362 34±1.522 41± 1.476 AZ11 35±3.214 37±2.327 42± 1.874 AZ12 38± 2.538 41± 1.781 46± 1.323 STD 46±2.429 53± 2.16 65± 1.871 Significant levels p <0.01 as compared with the respective control a Each value represents the means ± SD (n=6)
3h 34±1.414 44± 1.424 43±1.762 39± 2.306 39± 1.861 41± 1.472 35± 1.876 37±3.246 32± 1.159 29± 3.132 36±1.861 32± 1.672 43±1.871
Deterimation of % protection of antiinflammatory av tiv ity 80 70
% P r o t e c t io n
60 50
Series1 Series2
40
Series3 Series4
30 20 10
S T D
A Z 1 1
A Z 9
A Z 7
A Z 5
A Z 3
A Z 1
0
Compounds
Fig.-1: Percent protection antiinflammatory activity of 1-(2-((18Z)-4-substituted benzylidene-4,5-dihydro-5-oxo-2-phenylimidazol-1-yl)ethyl)-1, 2-dihydro-4-methyl2-oxoquinolin-7-yl sub
SOME NEW IMIDAZOLO QUINOLINE ANALOGS
98
P.Raghavendra et al.